Apoptosis in the mammalian thymus during normal histogenesis and under various in vitro and in vivo experimental conditions

In Vivo

Volumn 12, Issue 1, 1998, Pages 123-133

  Bodey, Bela ^a,d   Bodey Jr , Bela ^a   Kaiser, Hans E ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VIENNA   (Austria)

^d NONE   (United States)

Author keywords

Annexin V; Apoptosis; Apoptosis genes; Apoptotic bodies; Bad protein; Bax protein; Bcl 2; c myc; CD95 Fas APO 1 antigen; Condensation of cellular chromatin; p53; Phosphatidylserine (PS); Phospholipid asymmetry; Programmed cell death (PCD); Steroid treatment; Thymic cultures; Thymic histogenesis; Thymic irradiation; Thymic transplantation

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIINFECTIVE AGENT; CALCIUM ION; CALCIUM IONOPHORE; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; DNA; ENDONUCLEASE; FAS ANTIGEN; MEMBRANE PHOSPHOLIPID; PHOSPHATIDYLSERINE; PROTEIN P53; TOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CELL MEMBRANE; CELL STRUCTURE; CELL SUBPOPULATION; DNA DEGRADATION; FEMALE; FETUS; HISTOGENESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTHERMIA; MALE; MOUSE; NONHUMAN; NUCLEOSOME; RETICULOENDOTHELIAL SYSTEM; STROMA CELL; T LYMPHOCYTE; THYMOCYTE; THYMUS; ULTRAVIOLET IRRADIATION; VIRUS INFECTION; X RAY;

EID: 0031966024     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (147)

1. Glucksmann A: Cell deaths in normal vertebrate ontogeny. Biol Rev 26: 59-86, 1951.
2. Saunders JW: Death in embryonic systems. Science 154: 604-612, 1966.
3. Walker NI, Harmon BV, Gobe GC, Kerr JFR: Patterns of cell death. Meth Achiev Exp Pathol 13: 18-54, 1988.
4. cdc2 activation required for apoptosis. Science 263: 1143-1145, 1994.
5. King KL, Cidlowski JA: Cell cycle and apoptosis: common pathways to life and death. J Cell Biochem 58: 175-180, 1995.
6. Meikrantz W, Schlegel R: Apoptosis and the cell cycle. J Cell Biochem 58: 160-174, 1995.
7. Dou QP, An B, Yu C: Activation of cyclin E-dependent kinase by DNA-damage signals during apoptosis. Biochem Biophys Res Commun 214: 771-780, 1995.
8. White E: Life, death, and the pursuit of apoptosis. Genes Dev 10: 1-15, 1996.
9. Sachs L, Lotem J: Control of programmed cell death in normal and leukemic cells: new implication for therapy. Blood 82: 15-21, 1993.
10. Mountz JD, Zhou T, Wu J, Wang W, Su X, Cheng J: Regulation of apoptosis in immune cells. J Clin Immunol 15: 1-16, 1995.
11. Hockenbery D: Defining apoptosis. Am J Pathol 146: 16-19, 1995.
12. Ridet A, Guillouf C, Duchaud E, Cundari E, Fiore M, Moustacchi E, Rosselli F: Deregulated apoptosis is a hallmark of the Fanconi anemia syndrome. Cancer Res 57: 1722-1730, 1997.
13. Arends MJ, Wylle AH: Apoptosis: Mechanisms and roles in pathology. Int Rev Exp Pathol 32: 223-254, 1991.
14. Patel T, Gores GJ, Kaufmann SH: The role of proteases during apoptosis. FASEB J 10: 587-597, 1996.
15. Martin SJ, Green DR, Cotter TG: Dicing with death: dissecting the components of the apoptosis machinery. Trends Biochem Sci 19: 26-30, 1994.
16. Kerr JFR, Wylle AH, Currie AR: Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer 26: 239-257, 1972.
17. Wyllie AH: Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284: 555-556, 1980.
18. Wyllie AH, Kerr JFR, Currie AR: Cell death: The significance of apoptosis. Int Rev Cytol 68: 251-306, 1980.
19. Morris RG, Hargreaves AD, Duvall E, Wyllie AH: Hormone-induced cell death. 2. Surface changes in thymocytes undergoing apoptosis. Am J Pathol 115: 426-436, 1984.
20. Arends MJ, Morris RG, Wyllie AH: Apoptosis: The role of the endonuclease. Am J Pathol 136: 593-608, 1990.
21. Green DR, Bissonnette RP, Cotter TG: Apoptosis and Cancer. In: Important Advances in Oncology 1994 (DeVita VT, Hellman S, Rosenberg SA, eds). Philadelphia, J.B. Lippincott, pp. 37-52, 1994.
22. Savill J, Fadok V, Henson P, Haslett C: Phagocyte recognition of cells undergoing apoptosis. Immunol Today 14: 131-136, 1993.
23. Trauth BC, Klas C, Peters AMJ, Matzku S, Moller P, Falk W, Debatin K-M, Krammer PH: Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245: 301-305, 1989.
24. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66: 233-243, 1991.
25. Shi Y, Glynn JM, Guilbert LJ, Cotter TG, Bissonnette RP, Green DR: Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science 257: 212-214, 1992.
26. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, Hancock DC: Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119-128, 1992.
27. Korsmeyer SJ: Bcl-2: a repressor of lymphocyte death. Immunol Today 13: 285-288, 1992.
28. Goi K, Takagi M, Iwata S, Delia D, Asada M, Donghi R, Tsunematsu Y, Nakazawa S, Yamamoto H, Yokota J: DNA damage-associated dysregulation of the cell cycle and apoptosis control in cells with germ-line p53 mutation. Cancer Res 57: 1895-1902, 1997.
29. Hoffman B, Liebermann DA: Molecular controls of apoptosis: differentiation/growth arrest primary response genes, protooncogenes, and tumor suppressor genes as positive and negative modulators. Oncogene 9: 1807-1812, 1994.
30. Ehl S, Hoffmann-Rohrer U, Nagata S, Hengartner H, Zinkernagel R: Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo. J Immunol 156: 2357-2360, 1996.
31. Durkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H: Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 68: 421-427, 1992.
32. Calderhead DM, Buhlmann JE, van den Eertwegh AJM, Claassen E, Noelle RJ, Fell HP: Cloning of mouse Ox40: a T cell activation marker that may mediate T-B cell interactions. J Immunol 151: 5261-5271, 1993.
33. Smith CA, Farrah T, Goodwin RG: The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76: 959-962, 1994.
34. Nagata S: Fas and Fas ligand: a death factor and its receptor. Adv Immunol 57: 129-144, 1994.
35. Ogasawara J, Suda T, Nagata S: Selective apoptosis of CD4+CD8+ thymocytes by the anti-Fas antibody. J Exp Med 181: 485-491, 1995.
36. Alderson MR, Armitage RJ, Maraskovsky E, Tough TW, Roux E, Schooley K, Ramsdell F, Lynch DH: Fas transduces activation signals in normal human T lymphocytes. J Exp Med 178: 2231-2235, 1993.
37. Yonehara S, Ishii A, Yonehara M: A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 169: 1747-1756, 1989.
38. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S: Lethal effect of the anti-Fas antibody in mice. Nature 364: 806-809, 1993.
39. Suda T, Takahashi T, Golstein P, Nagata S: Molecular cloning and expression of the Fas ligand: a novel member of the tumor necrosis factor family. Cell 75: 1169-1178, 1993.
40. Suda T, Nagata S: Purification and characterization of the Fas ligand that induces apoptosis. J Exp Med 179: 873-878, 1994.
41. Nagata S, Golstein P: The Fas death factor. Science 267: 1449-1456, 1995.
42. Schulze-Osthoff K: The Fas/APO-1 receptor and its deadly ligand. Trends Cell Biol 4: 421-426, 1995.
43. Cohen PL, Eisenberg RA: Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 9: 243-269, 1991.
44. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356: 314-317, 1992.
45. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, Nagata S: Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76: 969-976, 1994.
46. Zhou T, Bluethmann H, Eldridge J, Berry K, Mountz JD: Abnormal thymocyte development and production of autoreactive T cells in TCR transgenic autoimmune mice. J Immunol 147: 466-474, 1991.
47. Zhou T, Mountz JD, Edwards III CK, Berry K, Bluethmann H: Defective maintenance of T cell tolerance to a superantigen in MRL-lpr/lpr mouse. J Exp Med 176: 1063-1072, 1992.
48. + T cells in MRL-lpr/lpr mice. Clues from a T cell receptor beta transgenic mouse. J Immunol 150: 3651-3667, 1993.
49. Owen-Schaub LB, Yonehara S, Crump WL III, Grimm E: DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. Cell Immunol 140: 197-205, 1992.
50. Klas C, Debatin K-M, Jonker RR, Krammer PH: Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol 5: 625-630, 1993.
51. Su X, Zhou T, Wu J, Jope R, Mountz JD: Dephosphorylation of a 65kD protein associated with signaling for Fas-mediated apoptosis. (Abstract) FASEB J 8: A218, 1994.
52. Packham G, Cleveland J: c-Myc and apoptosis. Biochim Biophys Acta 1242: 11-28, 1995.
53. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849-852, 1993.
54. Strasser A, Harris AW, Jacks T, Cory S: DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 79: 329-339, 1994.
55. Bodey B, Gröger AM, Bodey B Jr, Siegel SE, Kaiser HE: Immunocytochemical detection of p53 protein overexpression in primary human osteosarcomas. Anticancer Res 17: 493-498, 1997.
56. Bodey B, Gröger AM, Bodey B Jr, Siegel SE, Kaiser HE: Immunocytochemical detection of p53 protein expression in various childhood astrocytoma subtypes: Significance in tumor progression. Anticancer Res 17: 1187-1194, 1997.
57. Bodey B, Bodey B Jr, Gröger AM, Luck JV, Siegel SE, Taylor CR, Kaiser HE: Immunocytochemical detection of the p170 multidrug resistance (MDR) and the p53 tumor suppressor gene proteins in human breast cancer cells: Clinical and therapeutical significance. Anticancer Res 17: 1311-1318, 1997.
58. 1. Cancer Res 57: 2550-2554, 1997.
59. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379: 88-91, 1996.
60. Naumowski L, Cleary ML: Bcl-2 inhibits apoptosis associated with terminal differentiation of HL-60 myeloid leukemia cells. Blood 83: 2261-2266, 1994.
61. Reed JC: Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 7: 541-546, 1995.
62. Haldar S, Basu A, Croce CM: Bcl-2 is the guardian of microtubule integrity. Cancer Res 57: 229-233, 1997.
63. Oltvai Z, Milliman C, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog Bax that accelerates programmed cell death. Cell 74: 609-619, 1993.
64. Yuan J, Horvitz HR: The Caenorhabditis elegans genes ced-3 and ced4 act cell autonomously to cause programmed cell death. Dev Biol 138: 33-41, 1990.
65. Hengartner MO, Ellis RE, Horvitz HR: Caenorhabditis elegans gene ced-9 protects cells from programmed cell death. Nature 356: 494-499, 1992.
66. Steller H: Mechanisms and genes of cellular suicide. Science 267: 1445-1448, 1995.
67. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1-6, 1994.
68. Pourzand C, Rossier G, Reelfs O, Borner C, Tyrrell RM: The overexpression of bcl-2 inhibits UVA-mediated immediate apoptosis in rat 6 fibroblasts: evidence for the involvement of bcl-2 as an antioxidant. Cancer Res 57: 1405-1411, 1997.
69. Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thomberry NA, Wong WW, Yuan J: Human ICE/CED-3 protease nomenclature. Cell 87: 171, 1996.
70. Kumar S, Kinoshita M, Noda M, Copeland NG, Jenkins NA: Induction of apoptosis by the mouse Nedd 2 gene, which encodes a protein similar to the product of the Caenorhabditis elegans cell death gene ced-3 and the mammalian IL-1β-converting enzyme. Genes Dev 8: 1613-1626, 1994.
71. Wang L, Miura M, Bergeron B, Zhu H, Yuan J: Ich-1, an ICE/Ced-3 related gene, encodes both positive and negative regulators of programmed cell death. Cell 78: 739-750, 1994.
72. Kamens J, Paskind M, Hugunin M, Talanian RV, Allen H, Banach D, Bump N, Hackett M, Johnston CG, Li P, Mankovich JA, Terranova M, Ghayur T: Identification and characterization of ICH-2, a novel member of the interleukin-1β-converting enzyme family of cysteine proteases. J Biol Chem 270: 15250-15256, 1995.
73. Fernandes-Alnemri T, Litwack G, Alnemri ES: CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1β-converting enzyme. J Biol Chem 269: 30761-30764, 1995.
74. Fernandes-Alnemri T, Litwack G, Alnemri ES: Mch2, a new member of the apoptotic Ced-3/ICE cysteine protease gene family. Cancer Res 55: 2737-2742, 1995.
75. relIII members of the ICE/Ced-3 family of cysteine proteases. J Biol Chem 270: 15870-15876, 1995.
76. Duan H, Chinnaiyan AM, Hudson P, Wing JP, He WW, Dixit VM: ICE-LAP3, a novel mammalian homologue of the Caenorhabditis elegans cell death protein Ced-3 is activated during Fas- and tumor necrosis factor-induced apoptosis. J Biol Chem 271: 1621-1625, 1996.
77. Duan H, Orth K, Chinnaiyan AM, Poirier GG, Froelich CJ, He WW, Dixit VM: ICE-LAP6, a novel member of the ICE-Ced-3 gene family, is activated by the cytotoxic T cell protease granzyme B. J Biol Chem 271: 16720-16724, 1996.
78. Boldin MP, Goncharov TM, Goltsev YV, Wallach D: Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1 and TNF receptor-induced cell death. Cell 85: 803-815, 1996.
79. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC: Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371: 346-347, 1994.
80. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA: Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376: 37-43, 1995.
81. Sotensen CM: Apoptosis or planning a death. Biomedical Products (September, 1996 issue), pp 38-39, 1996.
82. Bodey B, Bodey B Jr, Kemshead JT, Siegel SE, Kaiser HE: Identification of neural crest derived cells within the cellular microenvironment of the human thymus employing a library of monoclonal antibodies raised against neuronal tissues. IN VIVO, 10: 39-47, 1996.
83. Ottaviani E, Franchini A, Franceschi C: Evolution of neuroendocrine thymus: studies on POMC-derived peptides, cytokines and apoptosis in lower and higher vertebrates. J Neuroimmunology 72: 67-74, 1997.
84. Bodey B, Bodey B Jr, Kaiser HE: Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network. In Vivo 11: 351-370, 1997.
85. Bodey B, Bodey B Jr, Kaiser HE: Cell culture observations of Postnatal Thymic Epithelium: An In Vitro Model for Growth and Humoral Influence on Intrathymic T Lymphocyte Maturation. IN VIVO 10: 515-526, 1996.
86. Perry SW, Epstein LG, Gelbard HA: Simultaneous in situ detection of apoptosis and necrosis in monolayer cultures by TUNEL and trypan blue staining. BioTechniques 22: 1102-1106, 1997.
87. Phillips HJ: Dye exclusion tests for cell viability. In: Tissue Culture: Methods and Applications (Kruse PF Jr, Patterson MK Jr, eds). New York, Academic Press, pp 406-408, 1973.
88. Allison DC, Ridolpho P: Use of a trypan blue assay to measure the deoxyribonucleic acid content and radioactive labeling of viable cells. J Histochem Cytochem 28: 700-703, 1980.
89. Krause AW, Carley WW, Webb WW: Fluorescent Erythrosin B is preferable to Trypan Blue as a vital exclusion dye for mammalian cells in monolayer culture. J Histochem Cytochem 32: 1084-1090, 1984.
90. Perry SW, Epstein LG, Gelbard HA: In situ trypan blue staining of monolayer cell cultures for permanent fixation and mounting. BioTechniques 22: 1020-1024, 1997.
91. Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119: 493-501, 1992.
92. Gold R, Schmied M, Giegerich G, Breitschopf H, Hartung HP, Toyka KV, Lassmann H: Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab Invest 71: 219-225, 1994.
93. Wijsman JH, Jonker RR, Keijzer R, van de Cees CJH, Cornelisse J, van Dierendonck JH: A new method to detect apoptosis in paraffin sections: in situ end-labeling of fragmented DNA. J Histochem Cytochem 41: 7-12, 1993.
94. Lovelace CIP, Zhang J, Vanek PG, Collier GB: Detecting apoptotic cells in situ. Biomed Products 21: 76-77, 1996.
95. Laster SM, Wood JG, Gooding LR: Tumor necrosis factor can induce both apoptotic and necrotic forms of cell lysis. J Immunol 141: 2629-2634, 1988.
96. Nakamura M, Yagi H, Ishii T, Kayaba S, Soga H, Gotoh T, Ohtsu S, Ogata M, Itoh T: DNA fragmentation is not the primary event in glucocorticoid-induced thymocyte death in vivo. Eur J Immunol 27: 999-1004, 1997.
97. Korsmeyer SJ: Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80: 879-886, 1992.
98. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F, Veronesi U: The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86: 499-504, 1994.
99. Haldar S, Jena N, Croce CM: Inactivation of bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92: 4507-4511, 1995.
100. Haldar S, Chintapalli J, Croce CM: Taxol-induced bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56: 1253-1255, 1996.
101. Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Neckers LM: Taxol-induced apoptosis and phosphorylation of bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 56: 1851-1854, 1996.
102. Vaux DL, Coly S, Adams JM: Bcl-2 gene promotes hematopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 355: 440-442, 1988.
103. Hockenbery DM, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334-336, 1990.
104. Hockenbery DM, Oltvai ZN, Yin X-M, Milliman CL, Korsmeyer SJ: Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75: 241-251, 1993.
105. Boise LH, Gonzalez-Garcia M, Postema CF, Ding L, Lindstein T, Turka LA, Mao X, Nunez G, Thompson CB: Bcl-X, a bcl-2 related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 597-608, 1993.
106. Hsu YT, Wolter KG, Youle RJ: Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. Proc Natl Acad Sci USA 94: 3668-3672, 1997.
107. Hsu YT, Yonle RJ: Nonionic detergents induce dimerization among members of the Bcl-2 family. J Biol Chem 272: 13829-13834, 1997.
108. Plum J, de Smedt M: Analysis of human prenatal and postnatal thymocytes with the antiTac monoclonal antibody and recombinant interleukin-2. Thymus 9: 149-158, 1987.
109. Janckila AJ, Yam LT, Li C-Y: Immunoalkaline phosphatase cytochemistry. Am J Clin Pathol 84: 476-480, 1985.
110. Cattoretti G, Berti E, Schiro R, D' Amato L, Valeggio C, Rilke F: Improved avidin-biotin-peroxidase complex (ABC) staining. Histol J 20: 75-80, 1988.
111. Bodey B, Zeltzer PM, Saldivar V, Kemshead J: Immunophenotyping of childhood astrocytomas with a library of monoclonal antibodies. Int J Cancer 45: 1079-1087, 1990.
112. Yam LT, Janckila AJ, Epremian BE, Li C-Y: Diagnostic significance of levamisole-resistant alkaline phosphatase in cytochemistry and immunocytochemistry. Am J Clin Pathol 91: 31-36, 1989.
113. Strasburger CJ, Amir-Zaltsman Y, Kohen F: The avidin-biotin reaction as an universal amplification system in immunoassays. Prog Clin Biol Res 285: 79-100, 1988.
114. Wilchek M, Bayer EA: Introduction to avidin-biotin technology. Methods Enzymol 184: 5-13, 1990.
115. Duhamel RC, Whitehead JS: Prevention of nonspecific binding of avidin. Methods Enzymol 184: 201-207, 1990.
116. Diamandis EP, Christopoulos TK: The biotin-(strept)avidin system: principles and applications in biotechnology. Clin Chem 37: 625-636, 1991.
117. Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison of ABC and unlabeled antibody (PAP) procedure. J Histochem Cytochem 29: 577-581, 1981.
118. Battifora H: The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. Lab Invest 55: 244-248, 1986.
119. Battifora H, Mehta P: The checkerboard tissue block. An improved multitissue control block. Lab Invest 63: 722-724, 1990.
120. Fujii Y, Okumura M, Takeuchi Y, Inada K, Nakahara K, Matsuda H, Tsujimoto Y: Bcl-2 expression in the thymus and periphery. Cell Immunol 155: 335-344, 1994.
121. Squier MK, Cohen JJ: Calpain, an upstream regulator of thymocyte apoptosis. J Immunol 158: 3690-3697, 1997.
122. Zhong LT, Sarafian T, Kane DJ, Charles AC, Mah SP, Edwards RH, Bredesen DE: Bcl-2 inhibits death of central neural cells induced by multiple agents. Proc Natl Acad Sci USA 90: 4533-4537, 1993.
123. Tewari M, Wolf FW, Seldin MF, O'Shea KS, Dixit VM, Turka LA: Lymphoid expression and regulation of A20, an inhibitor of programmed cell death. J Immunol 154: 1699-1706, 1995.
124. McConkey DJ, Orrenius S, Jondal M: Cellular signalling in programmed cell death (apoptosis). Immunol Today 11: 120-121, 1990.
125. MacDonald RR, Lees RK: Programmed death of autoreactive thymocytes. Nature 343: 642-644, 1990.
126. Alnemri ES, Femandes-Alnemri T, Haldar S, Croce C, Litwack G: Involvement of BCL-2 in glucocorticoid-induced apoptosis of human pre-B-leukemias. Cancer Res 52: 491-495, 1992.
127. Dieken ES, Meisfeld RL: Transcriptional transactivation functions localized to the glucocorticoid receptor N-terminus are necessary for steroid induction of lymphocyte apoptosis. Mol Cell Biol 12: 589-597, 1992.
128. Robertson NM, Bodine PVN, Hsu T-C, Alnemri ES, Litwack G: Modulator inhibits nuclear translocation of the glucocorticoid receptor and inhibits glucocorticoid-ibduced apoptosis in the human leukemic cell line CEM-C7. Cancer Res 55: 548-556, 1995.
129. Robertson NM, Zangrilli J, Femandes-Alnemri T, Friesen PD, Litwack G, Alnemri ES: Baculovirus P35 inhibits the glucocorticoid-mediated pathway of cell death. Cancer Res 57: 43-47, 1997.
130. Zhou T, Fleck M, Mueller-Ladner U, Yang P, Wang Z, Gay S, Matsumoto S, Mountz JD: Kinetics of Fas-induced apoptosis in thymic organ culture. J Clin Immunol 17: 74-84, 1997.
131. Komarova EA, Chemov MV, Franks R, Wang K, Armin G, Zelnick CR, Chin DM, Bacus SS, Stark GR, Gudkov AV: Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J 16: 1391-1400, 1997.
132. Shiono H, Fujii Y, Okumura M, Takeuchi Y, Inoue M, Matsuda H: Failure to downregulate Bcl-2 protein in thymic germinal center B cells in myasthenia gravis. Eur J Immunol 27: 805-809, 1997.
133. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
134. Tsujimoto Y, Finger L, Ynis J, Nowell PC, Croce CM: Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226: 1097-1099, 1984.
135. Tsujimoto Y, Cossman J, Jaffe E, Croce CM: Involvement of the bcl-2 gene in human follicular lymphoma. Science 228: 140-144, 1985.
136. Tsujimoto Y, Croce CM: Analysis of the structure, transcripts and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 83: 5214-5218, 1986.
137. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh J-T, Tu S-M, Campbell ML: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-6944, 1992.
138. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Butyan R: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143: 390-400, 1993.
139. Leek RD, Kaklamanis L, Pezella F, Gatter KC, Hanes AL: Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumors and in situ cancer. Br J Cancer 69: 135-139, 1994.
140. Pietenpol JA, Papadopoulos N, Markowitz S, Willson JKV, Kinzler KW, Vogelstein B: Paradoxical inhibition of solid tumor cell growth by bcl-2. Cancer Res 54: 3714-3717, 1994.
141. Lin K, Abraham KM: Targets of p56(lck) activity in immature thymoblasts: stimulation of the Ras/Raf/MAPK pathway. Internatl Immunol 9: 291-306, 1997.
142. Bodey B, Bodey B Jr, Siegel SE: Immunophenotypic characterization of infiltrating poly-and mononuclear cells in childhood brain tumors. Mod Pathol 8: 333-338, 1995.
143. Bodey B, Bodey B Jr, Siegel SE, Luck JV, Kaiser HE: Immunophenotypic characterization of human primary and metastatic melanoma infiltrating autologous immunological effector cells. Anticancer Res 16: 3439-3446, 1996.
144. Bowen ID, Bowen SM: Programmed cell death in tumours and tissues. New York, Chapman & Hill, 1990.
145. Cotter TG, Lennon SV, Glynn JG, Martin SJ: Cell death via apoptosis and its relationship to growth, development and differentiation of both tumour and normal cells. Anticancer Res 10: 1153-1159, 1990.
146. Zychlinsky A, Zheng LM, Liu CC, Young JD: Cytolytic lymphocytes induce both apoptosis and necrosis in target cells. J. Immunol 146: 393-400, 1991.
147. 2+-independent T cell-mediated cytotoxicity. J Exp Med 177: 195-200, 1993.